Avonex

Biogen and AbbVie bag FDA approval for multiple sclerosis drug

Zinbryta (daclizumab) is dosed once a month – in comparison with fortnightly and weekly for Biogen's Plegridy and Avonex, respectively - and is designed to be administered as a subcutaneous injection by ... patients by 45% when compared with Avonex

Bio investors react as Clinton tweet pledges pricing crackdown

Biogen (down 5.6%) has been under scrutiny for its pricing policy for first-generation multiple sclerosis drug Avonex (interferon beta-1a), which is among a number of older MS drugs

Biogen Idec plans phase III Alzheimer's trial before year-end

For the full-year the drug made $2.9bn, a great performance in its second year on the market and more than offsetting declining sales of injectable MS therapy Avonex (interferon ... Biogen Idec was also buoyed by a $40m contribution in the fourth-quarter

Dive in: gaining leadership in a therapeutic area

Meanwhile Biogen Idec's is the leader in multiple sclerosis (MS) since launching the first interferon beta 1a Avonex in 1996 in the US, re-launching Tysabri in 2006 after a

FDA approves Biogen Idec's long-acting MS therapy

Plegridy (peginterferon beta-1a) is a long-acting version of Biogen Idec's $3bn-a-year Avonex that has been a mainstay of MS therapy for years but is facing increased ... Plegridy is Biogen Idec's fifth MS treatment to reach the market joining Avonex,

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]